RGCRegencell Bioscience Holdings Limited
$7.61-58% 1Y
$7.61
$4.7552 weeks$52.88
RGC as reported
- Net income
- −$12M
Net income · +226% year on year · trailing twelve months to FY2026
- Free cash flow
- −$3.3M
Free cash flow · trailing twelve months to FY2025
- EPS
- −$2.37
EPS · +229% year on year · trailing twelve months to FY2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$12M | +226% | FY2026 |
| EPS | −$2.37 | +229% | FY2026 |
| ROE | −88% | n/a | FY2026 |
| ROA | −79% | n/a | FY2026 |
| Free cash flow | −$3.3M | n/a | FY2025 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Regencell Bioscience Holdings Limited (RGC) · Net incomeNet incomeRegencell Bioscience Holdings Limited (RGC)
Drug Manufacturers, Specialty & Generic
Ranks #38 of 39 by RyuScore